Cimzia (certolizumab pegol) / Astellas, UCB, Ferring - LARVOL DELTA

Immune profiling-informed immunomodulation associated with gestational extension in early-onset preeclampsia with monochorionic twins: a case report. (PubMed, Front Immunol) - "After multidisciplinary discussion and informed consent for off-label therapy in pregnancy, an immunomodulatory regimen was started at 31+1 weeks (prednisone 10 mg/day, hydroxychloroquine 200 mg bid, and a single 200 mg SC dose of certolizumab pegol). In this single MCDA twin pregnancy complicated by severe EOPE and concurrent immune-activation markers, initiation of a pregnancy-compatible immunomodulatory regimen was temporally associated with maternal clinical stabilization and a 3-4-week interval to delivery for fetal indications. Controlled studies with validated phenotyping, serial biomarkers (including sFlt-1/PlGF), standardized endpoints, and detailed safety follow-up are needed before attributing benefit or recommending this approach."

Journal • Cardiovascular • Gynecology • Hypertension • Immunology • Renal Disease • TNFA

Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial. (PubMed, Lancet Rheumatol) - P4 | "All treatment groups showed substantial improvements in patient-reported outcomes over time. Biological DMARDs produced somewhat greater gains in pain, fatigue, and physical quality of life measures than conventional treatments, though overall differences between groups were small. The results highlight that early treatment and effective disease control in rheumatoid arthritis lead to strong patient-reported benefits regardless of therapy type."

Clinical • Journal • Fatigue • Immunology • Inflammatory Arthritis • Pain • Rheumatoid Arthritis • Rheumatology

Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (clinicaltrials.gov) - P=N/A | N=40 | Recruiting | Sponsor: Marmara University

New trial • Vasculitis

A Delicate Balance: Managing Dermatologic Conditions with Immunomodulators in Pregnancy and Lactation (AAD 2026) - "For severe disease, cyclosporine is a preferred systemic agent, supported by extensive data...Among biologics, the TNF-α inhibitor certolizumab pegol is often favored due to its minimal placental transfer, a result of its pegylated structure lacking an Fc region...Conversely, agents with known teratogenicity, such as methotrexate and mycophenolate mofetil, are strictly contraindicated... The paradigm for managing chronic inflammatory skin disease in pregnancy has shifted from treatment avoidance to proactive, evidence-based management. A thorough understanding of each agent's risk profile, pharmacokinetics, and timing of exposure is essential for optimizing outcomes. This empowers clinicians to navigate complex therapeutic decisions, ensuring both maternal health and fetal well-being throughout pregnancy and lactation."

Immunomodulating • Atopic Dermatitis • Dermatitis • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Obstetrics • Psoriasis • Systemic Lupus Erythematosus

Comparative Recapture Rates and Retreatment Efficacy Endpoint Rates Following Biologic Treatment Interruption in Plaque Psoriasis (AAD 2026) - "TNF-α antagonists RR for PASI 75 ranged from 38.1% (infliximab) to 86.5% (certolizumab)...For PASI 90, consistent IL-17 antagonist retreatment showed consistently high REERs (63.4-100%), with brodalumab achieving the highest rates...Newer biologics, particularly IL-17 and IL-23 antagonists, demonstrate superior RRs and REERs compared to those of TNF-α inhibitors. This comparative data can guide treatment selection and inform patient expectations regarding the likelihood of regaining disease control after treatment interruptions, supporting evidence-based clinical decision-making in psoriasis management."

Clinical • Dermatology • Immunology • Psoriasis • IL23A

Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules. BIOBADADERM Registry. (AAD 2026) - " We analyzed crude incidence rates of overall, serious, recurrent, and infections of special interest in patients treated with etanercept, infliximab, certolizumab, adalimumab, ustekinumab, secukinumab, ixekizumab, brodalumab, bimekizumab, guselkumab, risankizumab, tildrakizumab, apremilast, and dimethyl fumarate. Modern systemic therapies for psoriasis show a favorable infection safety profile in real-world settings. IL-17 inhibitors appear to increase the risk of Candida infections, while some biologics may reduce the incidence of respiratory and viral infections."

Clinical • Candidiasis • Dermatology • Human Papillomavirus Infection • Immunology • Infectious Disease • Nephrology • Novel Coronavirus Disease • Psoriasis • Respiratory Diseases • IL17A

Beyond Trial-and-Error: Mechanism-Guided Use of Biologics in Scalp Psoriasis (AAD 2026) - "Ustekinumab offered modest scalp improvement but lacked dedicated trials. IL-17 inhibitors (secukinumab, ixekizumab, brodalumab, bimekizumab) consistently produced the most rapid clearance, with several maintaining high rates of complete response in long-term follow-up. IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) provided excellent durability, with real-world evidence confirming sustained clearance. No scalp-specific outcomes were reported for certolizumab... Biologic selection in scalp psoriasis can move beyond trial-and-error toward mechanism-guided therapy. IL-17 inhibitors are best suited for rapid scalp clearance, while IL-23 inhibitors may optimize long-term durability. These findings support the development of a practical, scalp-specific treatment algorithm to address one of the most visible and burdensome manifestations of psoriasis."

Dermatology • Immunology • Psoriasis • CD8 • IL22 • IL23A

Comparative risk of psoriatic arthritis in psoriasis patients on immunomodulators (AAD 2026) - "The immunomodulatory agents assessed included Adalimumab, Infliximab, Ixekizumab, Secukinumab, Tildrakizumab, Certolizumab pegol, Risankizumab, Etanercept, Guselkumab, and Ustekinumab. Inhibition of this inflammation by immunomodulators could impede PsA progression. Physicians can consider Risankizumab, Guselkumab, and Ustekinumab as treatment options for PsO patients with PsA risk factors to mitigate disease progression and improve patients’ quality of life."

Clinical • Immunomodulating • Cardiovascular • Dermatology • Diabetes • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Gout • Hypertension • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Obesity • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL23A • JAK1 • JAK3 • TNFA

Coverage generosity of novel anti-rheumatic drugs in Medicare Advantage and stand-alone Part D plans. (PubMed, Arthritis Rheumatol) - "The growing exclusions of self-administered DMARDs across several mechanisms of action and heterogeneity in coverage by plan type suggest potential barriers to accessing optimal RA treatments. Further monitoring of formulary adequacy and research into the clinical impacts of formulary exclusions are warranted."

Journal • Medicare • Reimbursement • US reimbursement • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology

RHEUMATOID FACTORS (RFs) DO NOT BIND FC-FREE CERTOLIZUMAB PEGOL, BUT DO BIND TO FC-CONTAINING BIOLOGICAL DMARDS, DRIVING IMMUNE COMPLEX FORMATION WHICH INDUCE CYTOKINE RELEASE FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) IN VITRO (EULAR 2026) - No abstract available

Preclinical • Immunology

SURVIVAL ON THERAPY OF CERTOLIZUMAB PEGOL IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND SPONDYLOARTHRITIS: 8-YEAR DATA FROM AN ITALIAN MULTICENTER REGISTER (EULAR 2026) - No abstract available

Clinical • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis

Rates of adverse pregnancy outcomes in pregnant women with antiphospholipid syndrome treated with standard of care without certolizumab pegol: comparison with the IMPACT study (EULAR 2026) - No abstract available

Adverse events • Clinical • Genetic Disorders • Hematological Disorders

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. (PubMed, Ann Rheum Dis) - "These updated EULAR recommendations provide consensus on RA management based on currently available evidence regarding efficacy, safety, and cost."

Journal • Cardiovascular • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology

Comparative risk of psoriatic arthritis in psoriasis patients on immunomodulators. (PubMed, Proc (Bayl Univ Med Cent)) - "The immunomodulatory agents assessed included adalimumab, infliximab, ixekizumab, secukinumab, tildrakizumab, certolizumab pegol, risankizumab, etanercept, guselkumab, and ustekinumab. Overall, IL-23 inhibitors risankizumab, guselkumab, and ustekinumab had the greatest decreased risk of PsA. Physicians can consider risankizumab, guselkumab, and ustekinumab as treatment options for psoriasis patients with PsA risk factors to mitigate disease progression and improve patients' quality of life."

Journal • Dermatology • Immunology • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL23A • JAK1 • JAK3 • TNFA

Central Nervous System Demyelination Associated with TNF-Alpha inhibitors: A 20-Year Systematic Review (ACTRIMS Forum 2026) - "Certolizumab showed the earliest onset (mean 8.7 months, SD 13.2), adalimumab (mean 17.7, SD 16.3), etanercept (mean 22.5, SD 34.7), Infliximab (mean 27.7, SD 17.0), & golimumab (mean 32.2, SD 56.0)...For the neurological disorder, only 17.4% of patients required long-term management with disease-modifying therapy, most commonly rituximab (26%), ocrelizumab (15%), and glatiramer with interferon combination (15%)...Following TNF-alpha-inhibitor cessation, 29.03% experienced worsening of their systemic autoimmune condition & 9.6 % required alternative biological therapy, commonly secukinumab, ustekinumab, tocilizumab, or methotrexate... TNF-α inhibitors, though effective for autoimmune diseases, may unpredictably be associated with CNS demyelination. Most often linked with adalimumab, etanercept, and infliximab. While many patients recover after discontinuing steroids, some have persistent deficits, underscoring the need for cautious use and close neurological..."

Review • CNS Disorders • Immunology • Multiple Sclerosis • Ocular Inflammation • Ophthalmology • Optic Neuritis

Demyelination Reported with Biologic Therapies for Rheumatologic and Inflammatory Bowel Diseases: Insights from FAERS (AAN 2026) - "Mechanistic classes included: anti–tumor necrosis factor (TNF)-α agents, anti-integrin antibodies (excluding natalizumab), anti-interleukin agents (including IL-12/23, IL-23, IL-17, IL-6, and IL-1 inhibitors), B-cell targeted therapies (excluding rituximab), and T-cell co-stimulation modulators... Safety signals for demyelination were identified with TNF-α inhibitors (infliximab, adalimumab, certolizumab pegol, golimumab, and etanercept) with a PRR of 7.34 (95% CI: 6.75–7.98), and abatacept, a selective T-cell co-stimulation modulator (PRR: 2.12; 95% CI: 1.41–3.20). No safety signals were observed for IL-12/23 inhibitors (ustekinumab), IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab), IL-23 inhibitors (mirikizumab, guselkumab, tildrakizumab, risankizumab), and anti-α4β7 integrin (vedolizumab). Reporting counts were insufficient for IL-6 inhibitors (tocilizumab and sarilumab), IL-1 inhibitors (anakinra, canakinumab, and rilonacept), and B-lymphocyte stimulator..."

Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • IL12A • IL17A • IL23A

Biological Treatment of Psoriasis-Data So Far. (PubMed, Pharmaceuticals (Basel)) - "Although topical treatments, systemic treatments (methotrexate, cyclosporine, acitretin), and phototherapy play a role, biologic agents have improved the efficacy of treatment of moderate-to-severe psoriasis. The purpose of this article is to comprehensively review the clinical trial data and evaluate and compare the key features of the currently approved biologic drugs for the treatment of psoriasis."

Journal • Review • Dermatology • Immunology • Inflammation • Psoriasis

FIRST-YEAR COST PER RESPONDER FOR BRODALUMAB COMPARED WITH OTHER BIOLOGIC THERAPIES FOR MODERATE TO SEVERE PLAQUE PSORIASIS IN CANADA (ISPOR 2026) - "The treatments (originators and available SEBs) included in this analysis were adalimumab, brodalumab, bimekizumab, etanercept, guselkumab, ixekizumab, risankizumab, secukinumab, and ustekinumab. Tildrakizumab, certolizumab, and infliximab were not part of the selected NMA and were therefore excluded from this analysis... At one year, brodalumab demontrates the greatest cost-effectiveness across PASI 100 and PASI 90 compared with other studied biologic therapies (originators and SEBs), providing optimal value for patients, prescribers, and payers."

Dermatology • Immunology • Psoriasis

Negotiations with participating drug companies will occur in 2026 and any negotiated and renegotiated prices will become effective January 1, 2028. (CMS Press Release) - "The selected drug list for the third cycle of negotiations is: Anoro Ellipta...Botox; Botox Cosmetic; Cimzia; Cosentyx; Entyvio...Orencia...Trulicity....Xeljanz; Xeljanz XR; Xolair."

Medicare • Allergy • Ankylosing Spondylitis • Asthma • Chronic Obstructive Pulmonary Disease • Crohn's disease • Idiopathic Arthritis • Immunology • Migraine • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Ulcerative Colitis

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (clinicaltrials.gov) - P4 | N=10 | Not yet recruiting | Sponsor: University of California, San Francisco

New P4 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

Case Report: Anti-TNF-α therapy-associated destructive thyroiditis and unmasking of latent amyloid A amyloidosis in rheumatoid arthritis. (PubMed, Front Immunol) - "We describe a 71-year-old man with a 16-year history of RA who developed destructive thyroiditis after initiation of certolizumab pegol...Treatment with the IL-6 receptor antibody tocilizumab rapidly normalized inflammatory markers and improved both renal function and gastrointestinal symptoms. This case highlights that TNF-α inhibition may paradoxically unmask underlying amyloidosis and induce autoimmune thyroiditis. Clinicians should monitor thyroid and systemic amyloid markers when introducing biologic therapy for long-standing RA."

Journal • Acute Kidney Injury • Amyloidosis • Endocrine Disorders • Immune Modulation • Immunology • Inflammatory Arthritis • Oncology • Renal Disease • Rheumatoid Arthritis • Rheumatology • IL6

Tumor Necrosis Factor-Alpha (TNF-α) Inhibitor Treatment in Hidradenitis Suppurativa: A Population-Based Retrospective Cohort Study of Comorbid Risks. (PubMed, Cureus) - "Using the TriNetX database, 15,416 patients with HS treated with TNF-α inhibitors (infliximab, adalimumab, certolizumab pegol, golimumab) and 201,737 untreated controls were identified. These findings emphasize the need for longitudinal studies examining the biologic safety and development of comorbidities in HS. Awareness of these associations can guide clinical monitoring and patient counseling regarding TNF-α inhibitor therapy."

Journal • Retrospective data • Autoimmune Hepatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammatory Bowel Disease • Oncology • Psoriasis • Pulmonary Disease • Respiratory Diseases • Sarcoidosis • Septic Shock • Tuberculosis

Central Nervous System Demyelination Associated With TNF-alpha Inhibitors: A 20-years Systematic Review and Meta-analysis (AAN 2026) - "Adalimumab (34.2%), etanercept (30.3%), and infliximab (28.4%) were predominant agents implicated with shortest onset after certolizumab (8.74 months) and longest after etanercept (22.5 months)...Disease modifying therapy such as rituximab and dimethyl fumarate were used in some cases... TNF-α inhibitors, though highly effective for autoimmune diseases, carry a rare but unpredictable risk of CNS demyelination. Most events were linked to adalimumab, etanercept, and infliximab. Although improved after discontinuation and steroid therapy."

Retrospective data • Review • CNS Disorders • Immunology • Multiple Sclerosis • Ocular Inflammation • Ophthalmology • Optic Neuritis

Nipocalimab and certolizumab combination therapy in participants with active rheumatoid arthritis despite prior treatment with advanced therapies: results from the phase 2a DAISY-RA study. (PubMed, RMD Open) - "Combination therapy of nipocalimab with certolizumab showed a similar outcome in the primary endpoint and secondary endpoints compared with certolizumab monotherapy in participants with active RA."

Journal • P2a data • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology • CRP

NORD-STAR: Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction (clinicaltrials.gov) - P4 | N=800 | Recruiting | Sponsor: Karolinska Institutet | Trial primary completion date: Mar 2019 ➔ Jun 2019

Trial primary completion date • Immunology • Rheumatoid Arthritis